Gene signatures in blood detect early Alzheimer’s disease
- DiaGenic is a leader in blood based biomarkers for early detection of Alzheimer’s disease
- DiaGenic develops products uniquely positioned to capitalize on the significant unmet needs related to Alzheimer’s diagnosis and treatment
- Strong partnerships and active dialogues regarding additional collaborations with key industry players
- Strong IP position, unique access to biobanks and mature technology in late stage development of products for commercialization in major markets
DiaGenic seeks to create value for patients, partners and investors by developing innovative and patient friendly in vitro diagnostic (IVD) products for early detection of diseases. The Company’s proprietary concept implies that a disease evokes systemic responses in the blood unique for the disease, which can be measured by using blood samples. DiaGenic is a world leader in identifying gene expression signatures in blood and is focused on the development of IVD biomarker products in the field of Alzheimer’s disease (AD).
DiaGenic’s gene signatures have different applications within the diagnostic work up of Alzheimer’s disease, and the focused portfolio consists of three products. The lead product candidate is aimed to detect Alzheimer’s disease in MCI (Mild Cognitive Impairment) patients within two years prior to onset of dementia. DiaGenic intends to develop this product, MCItect®, to FDA clearance.
DiaGenic also pursues development of two additional AD products; a new generation ADtect® for the detection of mild to moderate Alzheimer’s disease, and AMYtect™ for brain amyloid detection. AMYtect™ is currently being developed under a collaboration agreement with GE Healthcare.
DiaGenic controls patents in major markets including the US, EU and Japan, related to its technology and method to detect diseases of the central nervous system and cancer through gene expression in peripheral blood.